TOKYO – George Yeh, president of Taiwan Liposome Co. Inc. (TLC), told BioWorld Asia that in the coming years more trials for new drugs would take place in Asia, and that cross-country collaborations will help train a new generation of doctors in how to detect the potency and effectivity of treatments yet to reach the market.